Dermatology
| Atopic Dermatitis
Dermatology
Atopic Dermatitis
Efficacy and safety of baricitinib treatment in pediatric patients with atopic dermatitis aged 2 to less than 18 years (up to 3.6 years of exposure)
book_2
Source:
EADV Congress 2023 - Poster session
calendar_today
Published on Medfyle:
November 2023
In this medfyle
Pediatric patients with moderate-to-severe AD treated with baricitinib continued to show improvement in signs and symptoms of AD to 52 weeks without new safety signals.
Presenting Author
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the EADV Congress 2023. The content is developed by Infomedica in collaboration with the EADV.
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, or the EADV.
©2023 Infomedica. All rights reserved.
